Source:

源代码：

iCAD ProFound AI

iCAD ProFound AI

What You Should Know:

你应该知道的：

–

–

RadNet, Inc.

RadNet公司

, a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, and

，一家提供高质量、具成本效益的诊断影像服务和数字健康解决方案的全国领导者，以及

iCAD, Inc.

iCAD公司

, a global leader in

，全球领先的

AI-powered

人工智能驱动的

breast health solutions, announced that they have entered into a definitive

乳房健康解决方案，宣布他们已经达成了一项最终协议

merger

合并

agreement.

协议。

– Under the agreement, RadNet will acquire iCAD for $103M in an all-stock transaction.

根据协议，RadNet 将以 1.03 亿美元的全股票交易收购 iCAD。

Financial Details

财务细节

Based on RadNet’s closing price on Monday, April 14, 2025, the transaction is valued at approximately $103 million, or approximately $3.61 per share of iCAD common stock on a fully diluted basis. This represents an approximate 98% premium to iCAD stockholders, based on iCAD’s closing stock price on Monday, April 14, 2025.

基于RadNet在2025年4月14日（星期一）的收盘价，这笔交易的价值约为1.03亿美元，或者在完全稀释的基础上，相当于每股iCAD普通股约3.61美元。这相对于iCAD的股东来说，基于iCAD在2025年4月14日（星期一）的收盘股价，大约有98%的溢价。

According to the terms of the merger agreement, iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock they hold at the closing of the merger..

根据合并协议的条款，iCAD 股东在合并结束时将为其持有的每股 iCAD 普通股获得 0.0677 股 RadNet 普通股。

iCAD Background

iCAD背景

iCAD is focused on providing AI-powered solutions for earlier and more accurate cancer detection. Headquartered in Nashua, N.H., iCAD’s ProFound Breast Health Suite offers AI-powered mammography analysis for breast cancer detection, density assessment, and risk evaluation. ProFound is used by thousands of providers in over 50 countries.

iCAD专注于提供人工智能驱动的解决方案，以实现更早期和更精准的癌症检测。公司总部位于新罕布什尔州纳舒厄，其ProFound乳腺健康套件提供用于乳腺癌检测、密度评估和风险评估的人工智能乳腺X光分析技术。ProFound已被全球50多个国家的数千名医疗服务提供者使用。

iCAD estimates that its technology has been used to read over 40 million mammograms worldwide in the past five years, with nearly 30% being tomosynthesis..

iCAD估计，在过去的五年里，其技术已被用于全球范围内阅读超过4000万份乳腺X光片，其中近30%为断层合成。

“As we join forces with RadNet to create a broad offering of AI-driven solutions, we have the opportunity to redefine how breast cancer and other diseases are detected and treated. Together, we will work to expand access to cutting-edge tools, accelerate innovation and advance our product roadmaps, empowering radiologists with more precise, efficient and scalable solutions that should ultimately improve patient care and outcomes.

“随着我们与RadNet联手打造广泛的人工智能驱动解决方案，我们有机会重新定义乳腺癌及其他疾病的检测和治疗方法。通过共同努力，我们将扩展尖端工具的使用范围，加速创新并推进我们的产品路线图，为放射科医生提供更精准、高效且可扩展的解决方案，最终应能改善患者的护理与治疗效果。”

With current and future products in breast cancer detection, risk evaluation, density assessment and breast arterial calcification, we believe RadNet’s scale, access to data and clinical leadership will ensure our current and future products are brought to market, improving radiologist and patient workflow and clinical outcomes,” said Dana Brown, President and CEO of iCAD..

“凭借在乳腺癌检测、风险评估、密度评估和乳腺动脉钙化方面现有的及未来的产品，我们相信RadNet的规模、数据获取能力以及临床领导地位将确保我们的现有及未来产品顺利进入市场，改善放射科医生和患者的工作流程及临床结果，”iCAD的总裁兼首席执行官Dana Brown表示。